Israel's cabinet approves Health Ministry plan to speed up clinical trials

Israel's government on Sunday approved a national plan drawn up by the Ministry of Health to widen the scope of medical research and clinical trials in the country, according to a statement issued by the government's spokesperson division. The stated aim is to help new medical technologies reach the health system and to give patients access to novel therapies.

The measures centre on reducing bureaucracy and handing more authority to the institutions that carry out research. A central element is a system under which the ethics committees at different hospitals, known in Israel as Helsinki Committees, would recognise one another's approvals, so that a study cleared at one hospital does not need to go through the full process again elsewhere. The government statement said the plan would also allow applications to be filed digitally and processed more quickly.

What the plan is meant to change

According to the government, the plan should make procedures more efficient and reduce the time researchers wait for approval to begin a study. The expected result, in the government's account, is a larger number of research projects and clinical trials taking place in Israel.

The statement set out several intended benefits:

• Patients in Israel would gain access to advanced medical technologies at an earlier stage.
• Hospital medical teams would build up hands-on experience with those technologies.
• Israel's international standing in the field would be reinforced.
• The country would become more attractive to investment by multinational pharmaceutical and biotechnology companies.

The release listed several Ministry of Health units as connected to the announcement, including its Medical Directorate, its Medical Technologies, Informatics and Research Directorate, and its Planning, Budgeting and Pricing division.

What a Helsinki Committee is

Readers outside Israel may be more familiar with the terms institutional review board or research ethics committee. In Israel, the bodies that review proposed medical research involving human participants are called Helsinki Committees, a name taken from the Declaration of Helsinki, the international set of ethical principles for medical research on people. These committees operate within hospitals and must approve a study before it can enrol participants.

Because each hospital has its own committee, a trial planned across several sites may need separate approvals at each one. The mutual recognition mechanism described in the government's statement is intended to address that duplication.

Why clinical trials matter to a health system

Clinical trials are the studies through which new drugs, devices and treatment methods are tested on patients before they are adopted more widely. Countries that host many trials can offer some patients access to experimental treatments before they are generally available, and their doctors gain early familiarity with new approaches. Trials are frequently sponsored by international drug and biotechnology firms, which weigh factors such as regulatory speed when choosing where to run them. The government's statement links the plan directly to these considerations, framing faster approvals as a way to draw more such activity to Israel.

What the announcement does not say

The government statement is the only source for this report, and it leaves a number of questions open. It does not say whether the plan comes with a budget, or how much funding, if any, has been allocated. It gives no timetable for when the new procedures will take effect, and does not specify whether legislation or new regulations will be required.

The release does not quantify current approval waiting times or set a target for how far they should fall. It does not explain which specific powers will be decentralised, or to whom. It also does not describe how ethical oversight of research participants will be maintained once committees begin relying on each other's decisions, nor does it cite any response from hospitals, patient groups, researchers or industry.

All descriptions of the plan's expected benefits in this report reflect the government's own assessment.